PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17199783-6	2006	The level of urinary excretion of N-acetyl-beta-D-glucosaminidase was significantly higher in the patients who were taking long-term treatment (>10 years) with valproate, carbamazepine and combined therapy than those taking therapy shorter than 10 years (P < 0.01).	Carbamazepine	174-187	O-GlcNAcase	Homo sapiens	34-65	
21569539-5	2011	Measurement of urinary NAG/Cr index in the children who received CBZ also, was significantly higher than those who were not administered anti-epileptic drugs.	Carbamazepine	65-68	O-GlcNAcase	Homo sapiens	23-26	
21569539-7	2011	Children on anti-epileptic treatment with VPA or CBZ might demonstrate signs of renal tubular dysfunction, reflected by NAG/Cr activity index.	Carbamazepine	49-52	O-GlcNAcase	Homo sapiens	120-123	
17199783-9	2006	There was also a significant correlation between the serum concentration of carbamazepine and N-acetyl-beta-D-glucosaminidase excretion (r = 0.52, P < 0.01).	Carbamazepine	76-89	O-GlcNAcase	Homo sapiens	94-125	
7573767-0	1995	Is carbamazepine associated with NAG elevations suggestive of renal disease?	Carbamazepine	3-16	O-GlcNAcase	Homo sapiens	33-36	
7573767-1	1995	Elevations of urinary N-acetyl-beta-glucosaminidase (NAG) were found in previous studies of epileptic patients using carbamazepine.	Carbamazepine	117-130	O-GlcNAcase	Homo sapiens	22-51	
7573767-1	1995	Elevations of urinary N-acetyl-beta-glucosaminidase (NAG) were found in previous studies of epileptic patients using carbamazepine.	Carbamazepine	117-130	O-GlcNAcase	Homo sapiens	53-56	
7573767-2	1995	Since NAG can be a sensitive indicator of urinary tract problems, it was postulated that carbamazepine could be causing urinary tract damage.	Carbamazepine	89-102	O-GlcNAcase	Homo sapiens	6-9	
10029255-5	1999	Increased N-acetyl-beta-glucosaminidase activity was found in 50% of patients taking valproate and in 17.6% of patients taking carbamazepine.	Carbamazepine	127-140	O-GlcNAcase	Homo sapiens	10-39	
7694990-4	1994	The level of urinary excretion of N-acetyl-beta-glucosaminidase (u-NAG) was high in 29% of all patients, and 47% of VPA (SC > or = 60), 38% of CBZ, 25% of polytherapy, and 24% of VPA (SC < 60) groups.	Carbamazepine	146-149	O-GlcNAcase	Homo sapiens	34-63	
8214337-7	1993	Among the patients taking carbamazepine, only 11.1% exhibited high levels of NAG in urine.	Carbamazepine	26-39	O-GlcNAcase	Homo sapiens	77-80	
11077456-6	2000	After 6 months of therapy, patients treated with VPA and CBZ showed a significant increase in the urinary excretion of NAG and beta-Gal compared with baseline data and control values.	Carbamazepine	57-60	O-GlcNAcase	Homo sapiens	119-122